Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous natural killer cell-like CTLs

A preparation of cytotoxic T lymphocytes (CTLs) that express natural killer (NK)-like features (nCTLs), with potential immunomodulating and antineoplastic activities. The nCTLs are derived from autologous lymphocytes that have been in vitro exposed to autologous alpha-type-1 polarized dendritic cells that are pulsed with specific autologous tumor-associated antigens (TAAs); the nCTLs are subsequently expanded in the presence of the cytokine human interleukin-2 (IL-2). The generated nCTLs are potent CTLs that produce high amounts of granzyme B and perforin, and interferon-gamma (IFNg) with high killer activity and tumor-homing potential. Upon infusion of the autologous nCTLs, these cells specifically recognize the TAAs on the tumor cells, then bind to and directly lyse tumor cells.
Synonym:autologous aDC1-induced CTLs
autologous CTLs sensitized ex-vivo with autologous TAA-loaded alphaDC1
autologous natural killer-like cytotoxic lymphocytes
autologous nCTLs
autologous NK-like CTLs
in vitro DC-sensitized CTLs
in-vitro DC-sensitized autologous CTLs
therapeutic iNKT cells
therapeutic nCTLs
tumor neo-antigen-specific nCTLs
Search NCI's Drug Dictionary